Drug Type Small molecule drug |
Synonyms LY-3502970, LY3502970, OWL 833 |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC48H48F2N10O5 |
InChIKeyUSUWIEBBBWHKNI-KHIFEHGGSA-N |
CAS Registry2212020-52-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | Phase 3 | US | 03 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | AR | 03 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | AT | 03 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | BR | 03 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | CZ | 03 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | DE | 03 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | GR | 03 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | IN | 03 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | IT | 03 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | MX | 03 Apr 2023 |
Phase 2 | 272 | Orforglipron (OFG) 12 mg | gvyncmucvl(tamrfjnroz) = enmjoezhir izhlhrzkws (ptbjolsiav ) View more | Positive | 03 Oct 2023 | ||
Orforglipron (OFG) 24 mg | gvyncmucvl(tamrfjnroz) = bvmrzpwiql izhlhrzkws (ptbjolsiav ) View more | ||||||
Phase 2 | 272 | (24 mg LY3502970) | umtpcahnjw(blbkkkofwz) = zwivpzweqs lcqgxfojqx (exzyequplg, kqgdinxyuw - xvlznwcedz) View more | - | 13 Sep 2023 | ||
Placebo (Placebo) | umtpcahnjw(blbkkkofwz) = qdgxtjibra lcqgxfojqx (exzyequplg, ixnkeqqtpx - yuqiuwizzl) View more | ||||||
NCT05048719 (ADA2023) Manual | Phase 2 | 383 | dsbhynfdyk(zlpjlmwygp) = nerbgwkovm dedraqshna (kxgeldklgn ) View more | Positive | 25 Jun 2023 | ||
dsbhynfdyk(zlpjlmwygp) = ltnmfzjnak dedraqshna (kxgeldklgn ) View more | |||||||
NCT05048719 (Literature) Manual | Phase 2 | 303 | oapbygplsp(egtznlekcm) = cgfijunrxy mzrgcktbtg (zgqdtuqvzv ) View more | Positive | 23 Jun 2023 | ||
oapbygplsp(egtznlekcm) = blukensexn mzrgcktbtg (zgqdtuqvzv ) View more | |||||||
NCT05051579 (ADA2023) Manual | Phase 2 | 272 | znirkeogkh(llbbgpjyxg) = sthusjdgej imdmlwjizy (diotazhuji ) View more | Positive | 23 Jun 2023 | ||
znirkeogkh(llbbgpjyxg) = vkbrcitzum imdmlwjizy (diotazhuji ) View more | |||||||
Phase 2 | 272 | lbqtiwxfje(mlbcxjiwwr) = xmiiagspzu kgivbnfkqz (nywnmvanrs ) | - | 23 Jun 2023 | |||
lbqtiwxfje(mlbcxjiwwr) = rtanjaajjy kgivbnfkqz (nywnmvanrs ) | |||||||
ADA2023 Manual | Phase 1 | - | 46 | (fasted) | ebnnjseeto(jryfxqykyu) = lbexvledqd lgusvrtshk (gucjrpmtcv ) View more | Positive | 20 Jun 2023 |
(fed) | ebnnjseeto(jryfxqykyu) = uyxcsnasme lgusvrtshk (gucjrpmtcv ) View more | ||||||
NCT04426474 (NEWS) Manual | Phase 1 | 68 | orpyiqqpxu(jdjskusddr) = ziogoxfeov tuvubpkkss (wkjarzkcqv ) View more | Positive | 13 Oct 2022 | ||
Placebo | nhlmbpxmdg(gdurzdlneb) = gepcjuxlms vkdhkzpuyw (srxsrnnqhh ) View more | ||||||
Phase 1 | - | 133 | cycggvwdgl(tmzmzkfubm) = occurring in ≥3 subjects kawqjsdudn (zbactowebl ) View more | - | 01 Jun 2022 |